11 April 2024
11 April 2024
The current downsizing is separate from a company restructuring programme, which could see the dismissal of up to 8,000 employees.
The orphan drug designation adds to previous rare paediatric disease and fast-track designations for the drug.
Data from this study demonstrating improvement in HF hospitalisation rates is consistent with studies in populations using SGLT-2Is in T2D and CKD.
From nanoparticles to transdermal patches, Pharmaceutical Technology takes a look at the latest in drug delivery technologies for women's health.
A tamibarotene regimen demonstrated a 100% CR/CRi rate in a Phase II trial.
Encouraged by the performance of these drugs, companies are racing to commercialise their alternative obesity treatments.
Innate Pharma now plans to advance IPH45 towards clinical trials, with an investigational new drug (IND) application planned for later this year.
The Series B-2 funds are planned to finance the ongoing Phase I (NCT05103683) and a pivotal Phase II trial of TORL-1-23.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
